TRPM6 and familial primary hypomagnesemia: Molecular mechanisms underlying these side effects have been attributed to abnormal function of TRPM6, phenomena that were first described in patients carrying a mutation in the EGF gene and who have severe hypomagnesemia and cognitive disability.